Article Abstract

Is re-radiation for glioblastoma after progression associated with increased survival: to treat or not to treat?

Authors: Jose A. Carrillo, Santosh Kesari


Glioblastoma is the most common malignant brain tumor, representing 53.8% of all gliomas (1). Despite standard of care treatment with radiation and temozolomide chemotherapy, glioblastoma has a dismal prognosis with median survival of 14.6 months (2) and 20.9 months with addition of tumor-treating fields (Optune) (3). After tumor progression, treatment with re-irradiation and/or systemic therapy has yet to show improved overall survival leading to disagreement as to the best management of the patient who has progressed after standard of care treatment.

Article Options

Download Citation